The Impact of CTCs on Survival in Cervical Cancer

Krishnansu S. Tewari, MD, FACOG, FACS, discusses a trial looking at the impact of CTCs on overall survival among patients treated with chemotherapy plus bevacizumab for advanced cervical cancer.

Krishnansu S. Tewari, MD, FACOG, FACS, Professor and Director of Research, Principal Investigator, NRG Oncology and GOG Legacy, University of California Irvine, discusses a trial looking at the impact of circulating tumor cells (CTCs) on overall survival among patients treated with chemotherapy plus bevacizumab for advanced cervical cancer.

<<<

View more from SGO 2015